Hormesis reflects a bounded adaptive response that maximizes cellular resilience at a specific stress intensity, after which further increase overwhelms capacity and accelerates functional decline. This peak arises because low‑to‑moderate stressors transiently inhibit mTORC1 and activate AMPK‑SIRT1‑FOXO signaling, boosting proteostasis and mitochondrial efficiency without triggering irreversible damage pathways. As epigenetic age advances, chromatin becomes less permissive, limiting the transcriptional amplitude of these stress‑response genes and shifting the hormetic curve leftward—meaning the same stressor that was beneficial in youth becomes detrimental in old age. Crucially, the benefit does not stem from repair of accumulated lesions but from a temporary reallocation of resources toward defense, which wanes when the epigenome can no longer support a robust transcriptional surge.

Testable predictions

1. In isogenic cell lines, graded exposure to a hormetic agent (e.g., 0.1‑5 mM NaCl or 0.05‑2 mM H₂O₂) will produce a bell‑shaped curve of survival or ATP production, with the optimum shifting to lower concentrations in cells treated with epigenetic aging mimics (e.g., DNMT over‑expression or HDAC inhibition).
2. Measuring nascent RNA synthesis after a fixed sub‑lethal stress will show a maximal transcriptional burst at the hormetic optimum in young cells, whereas aged‑epigenotype cells will exhibit a blunted burst at the same stress level and a left‑shifted optimum.
3. Pharmacologically enhancing chromatin openness (using a low‑dose BET inhibitor) in aged cells should restore the height and rightward shift of the hormetic curve without altering baseline damage markers such as 8‑oxo‑dH or γH2AX.

Falsifiability If hormetic benefits persisted after stress removal and correlated directly with reductions in molecular damage irrespective of epigenetic state, the hypothesis would be refuted. Likewise, if epigenetic manipulation failed to alter the position or magnitude of the hormetic response curve, the proposed mechanism of epigenetically gated adaptive capacity would be unsupported.

Experimental outline

• Culture human fibroblasts passaged to define young (PD 15) and aged (PD 45) states; induce epigenetic aging in a subset via over‑expression of DNMT3B.
• Apply a logarithmic series of mild oxidative stress (H₂O₂) for 2 h, then assess cell viability, ROS levels, and global histone acetylation after 24 h.
• Perform EU‑labelled RNA sequencing immediately post‑stress to quantify transcriptional dynamics of HSP70, SOD2, and SIRT3.
• In parallel, treat aged‑epigenotype cells with a BET inhibitor (JQ1, 100 nM) during stress exposure and repeat viability and transcription assays.
• Statistical analysis will compare EC₅₀ values and maximal response amplitudes across conditions using two‑way ANOVA with post‑hoc Tukey tests.

This framework positions hormesis not as a damage‑repair tool but as an epigenetically tuned safety valve that optimizes survival within a narrow stress window, offering a clear, falsifiable route to dissect why longevity interventions lose potency with age.